Sanofi to acquire Ablynx for €3.9 Billion
- Details
- Category: Sanofi
Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion.
Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera®
- Details
- Category: Pfizer
Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan® (rituximab-US) / MabThera® (1). The trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
- Details
- Category: AstraZeneca
AstraZeneca has been recognised for its commitment to sustainability with two new, global accolades: the company has been listed as one of the 100 most sustainable companies in the world by Corporate Knights, the Toronto-based media and investment advisory firm, and has been commended for its use of renewable energy, as one of 122 multinational businesses who have made the RE100 commitment, by The Climate Group, an international non-profit organisation focused on accelerating climate action.
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
- Details
- Category: Novartis
Novartis today announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity
- Details
- Category: AstraZeneca
In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity following significant revision of its approach and adoption of a '5R framework' - right target, right patient, right tissue, right safety, right commercial potential.
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
- Details
- Category: Novartis
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice
- Details
- Category: Bayer
A report from the U.S. Food and Drug Administration (FDA) published in Pharmacoepidemiology & Drug Safety confirms the safety profile and effectiveness of Xarelto® (rivaroxaban) in people with atrial fibrillation (AF). The study is based on electronic healthcare data within the Mini-Sentinel safety programme in the US, reporting data on a large real-world population of over 115,000 people prescribed rivaroxaban or warfarin.
More Pharma News ...
- Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
- Novartis appoints Elizabeth Barrett as Oncology Head
- Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
- Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
- Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights
- Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
- Top 20 breaking World Pharma News of 2017